HBV DNA阳性的中晚期肝癌预后因素分析及抗病毒治疗对生存期的影响

臧允红; 丁明权; 何登明

HBV DNA阳性的中晚期肝癌预后因素分析及抗病毒治疗对生存期的影响

中国人民解放军第88医院肝病诊疗中心

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2459
- HTML全文浏览量: 8
- PDF下载量: 1067
- 被引次数: 0
出版历程
- 出版日期: 2011-06-20

Analysis of prognostic factors in HBV DNA positive patients with advanced stage liver cancer and effects of antiviral therapy on the patient's survival

摘要

摘要: 目的探讨HBV DNA阳性的中晚期原发性肝癌（PHC）预后的影响因素及抗病毒治疗对患者生存的影响。方法选择HBV DNA阳性的93例中晚期肝癌患者临床指标和随访资料,采用Kaplan-Meier法及Cox比例风险回归模型对可能影响其预后的因素进行单变量和多变量回归分析,重点分析病毒载量及核苷（酸）类似物抗病毒治疗对肝癌预后的影响。结果除GGT、Child-Pugh分级、门脉癌栓、治疗方式、治疗次数外,抗病毒治疗也是影响患者预后的重要因素,而病毒载量对预后无统计学意义（P>0.05）。结论虽病毒载量并不影响HBV DNA阳性患者的生存期,但抗病毒治疗仍是影响生存的重要因素,对于HBV DNA阳性的中晚期肝癌应积极抗病毒治疗,以期改善患者的生存。
- 肝肿瘤 /
- 肝炎病毒,乙型 /
- DNA,病毒 /
- 预后 /
- 比例危险度模型
Abstract: Objective To investigate the prognostic factors and effects of antiviral therapy on advanced PHC patients with HBV DNA positive.Methods The clinical and laboratory data of 93 patients with advanced stage and HBV DNA positive were selected.The factors affecting the prognosis were analyzed by Kaplan-Meier and Cox proportional hazard model, focusing on analysis of viral load and antiviral therapy on the PHC.Results Besides GGT, liver function of Child-Pugh classification, portal vein tumor thrombus, integrated treatment and number of treatment, antiviral therapy were important prognostic factors, while viral load on the prognosis of PHC were non-significant.Conclusion Although viral load does not affect the survival of patients, but the antiviral therapy is still an important factor affecting patient survival with advanced PHC with HBV DNA positive, so we should take antiviral therapy actively to improve patient survival.
- liver neoplasms /
- hepatitis B virus /
- DNA /
- viral /
- prognosis

HTML全文

参考文献(9)

[1]中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9 (6) :324.

[2]Beasley RP.Hepatits B virus themajor etiology of hepatocellullar-carcinoma[J].Cancer, 1988, 61 (10) :1942-1948.

[3]郑勤, 徐翰峰, 何耿劲, 等.肝动脉化疗栓塞术对肝癌患者乙肝病毒活动状态的影响[J].临床肿瘤学杂志, 2008, 13 (12) :1096-1098.

[4]Cheng SQ, Ding GH, Shi J, et al.Role of antivirus therapy in treatment of hepatocellular carcinoma with chronic hepatitis B infection[J].J Clin Oncol, 2005, 4 (6) :330-333.

[5]韩秋玉, 韦志平.拉米夫定联合肝动脉化疗对乙肝后肝癌病人的临床治疗观察[J].现代医药卫生, 2009, 25 (7) :984-985.

[6]占国清, 谭华炳, 朱琳, 等.抗病毒对肝动脉化疗栓塞治疗乙肝后中晚期肝癌的作用[J].临床肝胆病杂志, 2010, 26 (4) :423-431.

[7]郭西萍, 刘彦威, 王婉, 等.核苷类抗病毒治疗伴活动性肝硬化肝癌术后的临床观察[J].临床肝胆病杂志, 2010, 26 (4) :425-427.

[8]Paterlini P, Poussin K, Kew MC, et al.Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma[J].Hepatology, 1995, 21 (2) :313-321.

[9]Ohkubo K, Kato Y, Ichikawa T, et al.Viral load is a significant prognostic factor for hepatitis B virus associated hepatocellular carcinoma[J].Cancer, 2002, 94 (10) :2663-2668.

施引文献

资源附件(0)

访问统计